Author:
Agboluaje Elizabeth Oladoyin,Cui Shuolin,Grimsey Neil J.,Xiong May P.
Publisher
Springer Science and Business Media LLC
Reference59 articles.
1. Wang Y, Liu Z, Lin T-M, Chanana S, Xiong MP. Nanogel-DFO conjugates as a model to investigate pharmacokinetics, biodistribution, and iron chelation in vivo. Int J Pharm. 2018;538(1–2):79–86.
2. Liu Z, Qiao J, Nagy T, Xiong MP. ROS-triggered degradable iron-chelating nanogels: safely improving iron elimination in vivo. J Control Release. 2018;283:84–93.
3. Royal CD, Babyak M, Shah N, Srivatsa S, Stewart KA, Tanabe P, et al. Sickle cell disease is a global prototype for integrative research and healthcare. Adv Genet. 2021;2(1):e10037.
4. Farshadpour F, Taherkhani R, Farajzadeh H. Hepatitis B infection among β-thalassemia major patients in Bushehr province of southern Iran. J Immunoassay Immunochem. 2023;44(2):147–61.
5. ADMINISTRATION USFD: FDA approves first gene therapies to treat patients with sickle cell disease. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease (2023). Accessed 08 Dec 2023.